Boston Scientific Corporation $BSX Holdings Lowered by Erste Asset Management GmbH

Erste Asset Management GmbH trimmed its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 30.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 332,247 shares of the medical equipment provider’s stock after selling 142,919 shares during the period. Erste Asset Management GmbH’s holdings in Boston Scientific were worth $32,134,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of BSX. Murphy & Mullick Capital Management Corp lifted its holdings in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the second quarter valued at $26,000. Colonial Trust Co SC lifted its holdings in shares of Boston Scientific by 502.2% during the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 231 shares during the last quarter. Bangor Savings Bank lifted its holdings in shares of Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund purchased a new stake in shares of Boston Scientific during the fourth quarter valued at $29,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Canaccord reiterated a Buy rating on Boston Scientific, even though it trimmed its price target slightly to $70 from $71, signaling continued confidence in the company’s long-term outlook. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?
• Positive Sentiment: Truist also kept a Buy rating, though it cut its price target to $64 from $85, suggesting analysts still see meaningful upside despite a more cautious valuation view. Benzinga
• Positive Sentiment: The company announced plans for a $138 million medical device distribution facility in Indiana, which should expand operations and add 300 jobs, a sign of ongoing investment in growth and logistics capacity. Boston Scientific to open $138M medical device distribution facility in Indiana, adding 300 jobs
• Neutral Sentiment: Boston Scientific’s last reported quarter was strong, with revenue of $5.20 billion and EPS of $0.80 beating expectations, but the company also cut guidance due to stronger competition in cardiac devices and slower Watchman growth, creating a mixed fundamental backdrop. How Investors May Respond To Boston Scientific (BSX) Strong Q1 Beat But Cut Guidance On Watchman Growth
• Neutral Sentiment: Recent market commentary noted BSX has been trading above market averages on some sessions, but also lagging some peers, reflecting choppy investor sentiment rather than a clear trend. Boston Scientific Corp. stock underperforms Thursday when compared to competitors despite daily gains
• Negative Sentiment: The repeated reductions in price targets from analysts, including Truist and Canaccord, suggest expectations have reset lower, which can weigh on sentiment even when ratings remain positive. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?

Boston Scientific Stock Up 0.2%

BSX opened at $48.66 on Monday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The company has a market capitalization of $72.32 billion, a PE ratio of 20.36, a price-to-earnings-growth ratio of 0.91 and a beta of 0.56. The business has a 50-day moving average of $58.11 and a 200-day moving average of $76.53. Boston Scientific Corporation has a fifty-two week low of $47.17 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 3.37 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Insider Transactions at Boston Scientific

In related news, Director David C. Habiger bought 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Edward J. Ludwig bought 3,580 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, with a total value of $202,914.40. Following the transaction, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

BSX has been the subject of several analyst reports. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $55.00 target price (down from $75.00) on shares of Boston Scientific in a report on Thursday, May 28th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Boston Scientific in a report on Thursday, May 28th. Mizuho reduced their price objective on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Leerink Partners reduced their price objective on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research note on Thursday, May 28th. Finally, Raymond James Financial reissued an “outperform” rating and issued a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $85.92.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.